Atlas Trials

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Clinical trial NCT04307186 · COMPLETED

Trial details

NCT number
NCT04307186
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Central Nervous System Pathology
Start date
2020-11-18
Primary completion
2022-09-05
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.